Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death. The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clinical responses.

[1]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[2]  E. Holland,et al.  Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma , 2007, Oncogene.

[3]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[4]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[5]  D. Reardon,et al.  Molecularly targeted therapy for malignant glioma , 2007, Cancer.

[6]  P. Vogt,et al.  A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth , 2007, Oncogene.

[7]  G. Stamp,et al.  Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.

[8]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[9]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Xiaofeng Yang,et al.  Most C6 cells are cancer stem cells: evidence from clonal and population analyses. , 2007, Cancer research.

[11]  J. Folkman.  Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.

[12]  A. Brandes,et al.  Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.

[13]  A. Scott,et al.  A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors , 2007, Proceedings of the National Academy of Sciences.

[14]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[15]  H. Vogel,et al.  CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.

[16]  David A Hanauer,et al.  Bioinformatics approaches in the study of cancer. , 2007, Current molecular medicine.

[17]  Yonghong Xiao,et al.  FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis , 2007, Cell.

[18]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[19]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[20]  Tom Misteli,et al.  Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression , 2007, Cell.

[21]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[22]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[23]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[24]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[25]  L. Chin,et al.  Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. , 2007, Genes & development.

[26]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[27]  J. Buckner,et al.  The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. , 2007, Neuro-oncology.

[28]  I. Bayazitov,et al.  A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.

[29]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[30]  M. Horsman,et al.  Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. , 2006, Cancer research.

[31]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[32]  G. Broggi,et al.  Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells , 2006, Nature.

[33]  L. Chin,et al.  Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. , 2006, Cancer research.

[34]  A. Iafrate,et al.  Expression of Oligodendroglial and Astrocytic Lineage Markers in Diffuse Gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2 , 2006, Journal of neuropathology and experimental neurology.

[35]  C. Johannessen,et al.  A negative feedback signaling network underlies oncogene-induced senescence. , 2006, Cancer cell.

[36]  S. Gabriel,et al.  Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.

[37]  Fenghua Liu,et al.  A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. , 2006, Cancer research.

[38]  S. Horvath,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006, Proceedings of the National Academy of Sciences.

[39]  F. Feng,et al.  Integration of EGFR inhibitors with radiochemotherapy , 2006, Nature Reviews Cancer.

[40]  I. Jonassen,et al.  Angiogenesis-independent tumor growth mediated by stem-like cancer cells , 2006, Proceedings of the National Academy of Sciences.

[41]  N. Hay,et al.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. , 2006, Cancer cell.

[42]  B. Birlik,et al.  Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas , 2006, Neuropathology and applied neurobiology.

[43]  Gary L Gallia,et al.  PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.

[44]  Yuri Kotliarov,et al.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. , 2006, Cancer research.

[45]  P. Hawkins,et al.  Signalling through Class I PI3Ks in mammalian cells. , 2006, Biochemical Society transactions.

[46]  S. Morrison,et al.  Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing , 2006, Nature.

[47]  G. Evan,et al.  The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. , 2006, Genes & development.

[48]  Tony Hunter,et al.  Turnover of the Active Fraction of IRS1 Involves Raptor-mTOR- and S6K1-Dependent Serine Phosphorylation in Cell Culture Models of Tuberous Sclerosis , 2006, Molecular and Cellular Biology.

[49]  Ronald A. DePinho,et al.  Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.

[50]  R. Stupp,et al.  Brain tumors: molecular biology and targeted therapies. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[52]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[53]  T. Cloughesy,et al.  Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. , 2006, Cancer research.

[54]  C. Heldin,et al.  Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.

[55]  Keara M. Lane,et al.  ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. , 2006, Cancer research.

[56]  Susan M. Chang,et al.  Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  S. Vandenberg,et al.  PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.

[58]  T. Mak,et al.  Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[59]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[60]  A. Levine,et al.  The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.

[61]  D. Louis,et al.  AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. , 2006, Cancer research.

[62]  H. Jiang,et al.  Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo , 2006, Cancer Gene Therapy.

[63]  William A Weiss,et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.

[64]  M. Neeman,et al.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. , 2006, Cancer cell.

[65]  C. James,et al.  Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response , 2006, Clinical Cancer Research.

[66]  H. Li,et al.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.

[67]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[68]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[69]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Teramoto,et al.  The expression of matrix metalloproteinase-2 and-9 in human gliomas of different pathological grades , 2006, Brain Tumor Pathology.

[71]  Ximing J. Yang,et al.  The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.

[72]  V. P. Collins,et al.  CDKN 2 ( p 16 / MTS 1 ) Gene Deletion or CDK 4 Amplification Occurs in the Majority of Glioblastomast , 2006 .

[73]  H. Hollema,et al.  TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme , 2006, Journal of Neuro-Oncology.

[74]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[76]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[77]  Susan M. Chang,et al.  Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 , 2005, Clinical Cancer Research.

[78]  Stephen W. Fesik,et al.  Promoting apoptosis as a strategy for cancer drug discovery , 2005, Nature Reviews Cancer.

[79]  R. Parsons,et al.  Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice , 2005, Current Biology.

[80]  Inna N Lavrik,et al.  Caspases: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.

[81]  G. Reifenberger,et al.  Genetic alteration and expression of the phosphoinositol‐3‐kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas , 2005, Neuropathology and applied neurobiology.

[82]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[83]  B. Williams,et al.  Essential role for Ras signaling in glioblastoma maintenance. , 2005, Cancer research.

[84]  Mitchel S Berger,et al.  Neural stem cells and the origin of gliomas. , 2005, The New England journal of medicine.

[85]  E. Holland,et al.  Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. , 2005, Cancer research.

[86]  B. Scheithauer,et al.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Dawen Zhao,et al.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. , 2005, Cancer cell.

[88]  Susan M. Chang,et al.  Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme , 2005, Investigational New Drugs.

[89]  P. Pandolfi,et al.  Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. , 2005, Cancer research.

[90]  M. Berger,et al.  Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.

[91]  R. Kalluri,et al.  Endogenous inhibitors of angiogenesis. , 2005, Cancer research.

[92]  D. Botstein,et al.  Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Ivan Smirnov,et al.  Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma , 2005, Clinical Cancer Research.

[94]  P. Pandolfi,et al.  mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. , 2005, Neoplasia.

[95]  R. Kiss,et al.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[97]  E. Holland,et al.  Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. , 2005, Cancer research.

[98]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[99]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[100]  K. Aldape,et al.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.

[101]  N. Amariglio,et al.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. , 2005, Cancer research.

[102]  W. Weiss,et al.  RNA interference against a glioma-derived allele of EGFR induces blockade at G2M , 2005, Oncogene.

[103]  R. McLendon,et al.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. , 2005, Molecular cancer therapeutics.

[104]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[105]  M. Weller,et al.  BCL‐2‐induced glioma cell invasiveness depends on furin‐like proteases , 2004, Journal of neurochemistry.

[106]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[107]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[108]  Daniel J. Brat,et al.  Genetic and hypoxic regulation of angiogenesis in gliomas , 2004, Journal of Neuro-Oncology.

[109]  D. Gutmann,et al.  Pten Loss Causes Hypertrophy and Increased Proliferation of Astrocytes In vivo , 2004, Cancer Research.

[110]  Michael E. Berens,et al.  Molecular Mechanisms of Glioma Cell Migration and Invasion , 2004, Journal of Neuro-Oncology.

[111]  R. Mikkelsen,et al.  Inhibition of the Type III Epidermal Growth Factor Receptor Variant Mutant Receptor by Dominant-Negative EGFR-CD533 Enhances Malignant Glioma Cell Radiosensitivity , 2004, Clinical Cancer Research.

[112]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[113]  T. Mak,et al.  p53-dependent inhibition of FKHRL1 in response to DNA damage through protein kinase SGK1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[114]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[115]  A. Merlo,et al.  Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation* , 2004, Journal of Biological Chemistry.

[116]  H. Dvorak,et al.  VEGF‐A Angiogenesis Induces a Stable Neovasculature in Adult Murine Brain , 2004, Journal of neuropathology and experimental neurology.

[117]  Johannes Vogel,et al.  Massive Inborn Angiogenesis in the Brain Scarcely Raises Cerebral Blood Flow , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[118]  G. Fuller,et al.  Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas , 2004, Laboratory Investigation.

[119]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[120]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[121]  M. Rosenblum,et al.  Dose-Dependent Effects of Platelet-Derived Growth Factor-B on Glial Tumorigenesis , 2004, Cancer Research.

[122]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[123]  Jee-Yin Ahn,et al.  PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[124]  N. Dyson,et al.  Molecular mechanisms of E2F-dependent activation and pRB-mediated repression , 2004, Journal of Cell Science.

[125]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[126]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[127]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[128]  M. Berger,et al.  Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. , 2004, Cancer research.

[129]  G. Melino,et al.  Regulation of the apoptosis–necrosis switch , 2004, Oncogene.

[130]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[131]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[132]  G. Reifenberger,et al.  Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. , 2004, Journal of the National Cancer Institute.

[133]  Werner Paulus,et al.  Regulators of G‐Protein Signaling 3 and 4 (RGS3, RGS4) Are Associated with Glioma Cell Motility , 2004, Journal of neuropathology and experimental neurology.

[134]  E. Fuchs,et al.  Defining the Epithelial Stem Cell Niche in Skin , 2004, Science.

[135]  M. Ewen,et al.  The cell cycle and the retinoblastoma protein family , 1994, Cancer and Metastasis Reviews.

[136]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  T. Mak,et al.  p 53-dependent inhibition of FKHRL 1 in response to DNA damage through protein kinase SGK 1 , 2004 .

[138]  Chao Zhang,et al.  Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. , 2003, Cancer research.

[139]  Jesse D. Martinez,et al.  Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). , 2003, Cancer letters.

[140]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[141]  G. Fuller,et al.  IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[142]  C. Beaudry,et al.  Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis , 2003, Journal of Cell Science.

[143]  Eytan Domany,et al.  Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. , 2003, Cancer research.

[144]  G. Reifenberger,et al.  Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl‐lnositol‐3′‐Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas , 2003, Brain pathology.

[145]  B. Pyrzyńska,et al.  TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways , 2003, Brain pathology.

[146]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[147]  Irving L. Weissman,et al.  Normal and leukemic hematopoiesis: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[148]  A. Ciechanover,et al.  HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[149]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[150]  Susan M. Chang,et al.  33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma , 2003 .

[151]  M. Weller,et al.  Adenoviral natural born killer gene therapy for malignant glioma. , 2003, Human gene therapy.

[152]  David E. Misek,et al.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. , 2003, The American journal of pathology.

[153]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. , 2003, Cancer research.

[154]  K. Alitalo,et al.  Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[155]  J. Winkles,et al.  TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. , 2003, Cytokine & growth factor reviews.

[156]  Paul S Mischel,et al.  Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.

[157]  Paul S Mischel,et al.  Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.

[158]  W. Cavenee,et al.  Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. , 2003, The American journal of pathology.

[159]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[160]  William A Weiss,et al.  Genetic determinants of malignancy in a mouse model for oligodendroglioma. , 2003, Cancer research.

[161]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[162]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[163]  D. Gutmann,et al.  Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. , 2003, Cancer research.

[164]  P. Dirks,et al.  A human brain tumor-derived PDGFR-α deletion mutant is transforming , 2003, Oncogene.

[165]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[166]  H. Naganuma,et al.  A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents , 2003, British Journal of Cancer.

[167]  A. Scott,et al.  A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[168]  R. Jorissen,et al.  Epidermal growth factor receptor , 2003 .

[169]  Motoo Nagane,et al.  Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. , 2002, Cancer research.

[170]  K. Aldape,et al.  Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. , 2002, Cancer research.

[171]  J. Massagué,et al.  Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage , 2002, Nature.

[172]  G. Fuller,et al.  Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. , 2002, Cancer research.

[173]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[174]  M. Eilers,et al.  Negative regulation of the mammalian UV response by Myc through association with Miz-1. , 2002, Molecular cell.

[175]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[176]  A. Chakravarti,et al.  The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. , 2002, Cancer research.

[177]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[178]  Raymond Sawaya,et al.  Necrosis and Glioblastoma: A Friend or a Foe? A Review and a Hypothesis , 2002, Neurosurgery.

[179]  M. Israel,et al.  Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.

[180]  J. Ott,et al.  The p53MH algorithm and its application in detecting p53-responsive genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[181]  Hong Wu,et al.  Essential Role of AKT-1/Protein Kinase Bα in PTEN-Controlled Tumorigenesis , 2002, Molecular and Cellular Biology.

[182]  A. Jochemsen,et al.  Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53* , 2002, The Journal of Biological Chemistry.

[183]  Arnold J Levine,et al.  p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. , 2002, Genes & development.

[184]  R. DePinho,et al.  Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. , 2002, Cancer cell.

[185]  E. Lam,et al.  Control of Cell Cycle Exit and Entry by Protein Kinase B-Regulated Forkhead Transcription Factors , 2002, Molecular and Cellular Biology.

[186]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[187]  P. Pandolfi,et al.  Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. , 2002, Cancer cell.

[188]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[189]  D. Gutmann,et al.  Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo , 2002, Oncogene.

[190]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[191]  M. Mareel,et al.  The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness , 2001, The Journal of cell biology.

[192]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[193]  Brian A. Hemmings,et al.  Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane , 2001, Science.

[194]  David E. Misek,et al.  Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. , 2001, Cancer research.

[195]  W. Cavenee,et al.  Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. , 2001, Journal of neurosurgery.

[196]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[197]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[198]  A. Scott,et al.  Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.

[199]  M. Weller,et al.  CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.

[200]  K. Aldape,et al.  Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. , 2001, Cancer research.

[201]  C. Beaudry,et al.  Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. , 2001, Cancer research.

[202]  M. Weller,et al.  Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2 , 2001, The Journal of Neuroscience.

[203]  R. McLendon,et al.  A genetically tractable model of human glioma formation. , 2001, Cancer research.

[204]  Ho-Keung Ng,et al.  Detection of Multiple Gene Amplifications in Glioblastoma Multiforme Using Array-Based Comparative Genomic Hybridization , 2001, Laboratory Investigation.

[205]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[206]  M. Weller,et al.  Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. , 2001, Cancer research.

[207]  L. Ashworth,et al.  Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family. , 2001, Genomics.

[208]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[209]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[210]  P. Lowenstein,et al.  Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU , 2001, Cancer Gene Therapy.

[211]  P. Black,et al.  Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. , 2000, Cancer research.

[212]  Karlyne M. Reilly,et al.  Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects , 2000, Nature Genetics.

[213]  D. Osoba,et al.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.

[214]  T. Nishizaki,et al.  Clinical evidence of distinct subgroups of astrocytic tumors defined by comparative genomic hybridization. , 2000, Human pathology.

[215]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[216]  R. Medema,et al.  AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1 , 2000, Nature.

[217]  T. Ryken,et al.  Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. , 2000, Surgical neurology.

[218]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[219]  R. Honda,et al.  Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase , 2000, Oncogene.

[220]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[221]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[222]  E. Hudson,et al.  Regulation of P311 Expression by Met-Hepatocyte Growth Factor/Scatter Factor and the Ubiquitin/Proteasome System* , 2000, The Journal of Biological Chemistry.

[223]  M. Wolter,et al.  Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. , 1999, Cancer research.

[224]  J. Dichgans,et al.  BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[225]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[226]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[227]  D. H. Randle,et al.  Tumor spectrum in ARF-deficient mice. , 1999, Cancer research.

[228]  A. Kimchi,et al.  Structure–function analysis of an evolutionary conserved protein, DAP3, which mediates TNF‐α‐ and Fas‐induced cell death , 1999, The EMBO journal.

[229]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[230]  M. Hatten.  Central nervous system neuronal migration. , 1999, Annual review of neuroscience.

[231]  J. Dichgans,et al.  BCL‐2 promotes migration and invasiveness of human glioma cells , 1998, FEBS letters.

[232]  H. Varmus,et al.  Modeling mutations in the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. , 1998, Genes & development.

[233]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[234]  M. Nistér,et al.  Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.

[235]  L. Deangelis,et al.  Malignant glioma: Who benefits from adjuvant chemotherapy? , 1998, Annals of neurology.

[236]  S. Yamamoto,et al.  Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. , 1998, Human gene therapy.

[237]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[238]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[239]  Tomohiko Maehama,et al.  The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate* , 1998, The Journal of Biological Chemistry.

[240]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[241]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[242]  R. Carroll,et al.  Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. , 1998, Neurosurgery.

[243]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[244]  A. Pawson,et al.  Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.

[245]  G. Cooper,et al.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1 , 1997, Molecular and cellular biology.

[246]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[247]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[248]  T. Hunter,et al.  Focal Adhesion Kinase Overexpression Enhances Ras-dependent Integrin Signaling to ERK2/Mitogen-activated Protein Kinase through Interactions with and Activation of c-Src* , 1997, The Journal of Biological Chemistry.

[249]  J. Slattery,et al.  Chemotherapy response criteria in malignant glioma , 1997, Neurology.

[250]  A. Aguzzi,et al.  Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice , 1997, Oncogene.

[251]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[252]  W Arap,et al.  Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.

[253]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[254]  T. Hunter,et al.  Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex: involvement of the Grb2, p130cas, and Nck adaptor proteins , 1997, Molecular and cellular biology.

[255]  John Calvin Reed,et al.  Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. , 1997, The American journal of pathology.

[256]  J. Uhm,et al.  Mechanisms of Glioma Invasion: Role of Matrix-Metalloproteinases , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[257]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[258]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[259]  A. Kyritsis,et al.  Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. , 1996, Oncogene.

[260]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[261]  J. Pouysségur,et al.  Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway* , 1996, The Journal of Biological Chemistry.

[262]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[263]  J. Downward,et al.  Activation of phosphoinositide 3‐kinase by interaction with Ras and by point mutation. , 1996, The EMBO journal.

[264]  P. Black,et al.  Microvessel density is a prognostic indicator for patients with astroglial brain tumors , 1996, Cancer.

[265]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[266]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[267]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[268]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[269]  C. Heldin,et al.  Platelet‐derived growth factor in human glioma , 1995, Glia.

[270]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[271]  I. Pastan,et al.  Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[272]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[273]  M. Weller,et al.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. , 1995, The Journal of clinical investigation.

[274]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[275]  J. J. Bernstein,et al.  Glioblastoma Cells Do Not Intravasate into Blood Vessels: 124 , 1995, Neurosurgery.

[276]  T. Hunter,et al.  Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.

[277]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[278]  K. Kinzler,et al.  Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.

[279]  D. Louis,et al.  The retinoblastoma gene is involved in malignant progression of astrocytomas , 1994, Annals of neurology.

[280]  J. Bruner,et al.  Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. , 1994, Cancer research.

[281]  M. Weller,et al.  Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. , 1994, The Journal of clinical investigation.

[282]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[283]  P. Meltzer,et al.  Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. , 1994, Cancer research.

[284]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[285]  J. Bruner,et al.  Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. , 1994, Cancer research.

[286]  I. Bahar,et al.  [Epidermal growth factor receptor]. , 1994, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[287]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[288]  S. Brem,et al.  Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. , 1994, Cancer research.

[289]  D. Louis.  The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[290]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[291]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[292]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[293]  J. Glowinski,et al.  An Abundant mRNA of the Embryonic Brain Persists at a High Level in Cerebellum, Hippocampus and Olfactory Bulb During Adulthood , 1993, The European journal of neuroscience.

[294]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[295]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[296]  D. McCormick.  Secretion of cathepsin B by human gliomas in vitro , 1993, Neuropathology and applied neurobiology.

[297]  W. Lee,et al.  Retinoblastoma protein and the cell cycle. , 1993, Current opinion in genetics & development.

[298]  K. Plate,et al.  Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[299]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[300]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[301]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[302]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[303]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[304]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[305]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[306]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[307]  S B Green,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.

[308]  C. James,et al.  Clonal genomic alterations in glioma malignancy stages. , 1988, Cancer research.

[309]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[310]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[311]  T. Libermann,et al.  Expression of epidermal growth factor receptors in human brain tumors. , 1984, Cancer research.

[312]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[313]  E. Alexander,et al.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.

[314]  F. Segal,et al.  A CHARACTERIZATION OF FIBRANT SEGAL CATEGORIES , 2006, math/0603400.